Semih Gungor

Dr. Semih Gungor

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in The Clinical Journal of Pain
Verified
Journal Article
Closed access
PDF file
RARohit Aiyer
Rohit Aiyer
NMNeel Mehta
Neel Mehta
SGSemih Gungor
Semih Gungor
AGAmitabh Gulati
Amitabh Gulati
Objective: To investigate the efficacy of N-methyl-D-aspartate receptor (NMDAR) antagonists for neuropathic pain (NeuP) and review literature to determine if specific pharmacologic agents provide adequate NeuP relief.Methods: Literature was reviewed on PubMed using a variety of key words for 8 NMDAR antagonists. These key words include: “Ketamine and Neuropathy,” “Ketamine and Neuropathic Pain,” “Methadone and Neuropathy,” “Methadone and Neuropathic Pain,” “Memantine and Neuropathic pain,” “Memantine and Neuropathy,” “Amantadine and Neuropathic Pain,” “Amantadine and Neuropathy,” “Dextromethorphan and Neuropathic Pain,” “Dextromethorphan and Neuropathy,” “Carbamazepine and Neuropathic Pain,” “Carbamazepine and Neuropathy,” “Valproic Acid and Neuropathy,” “Valproic Acid and Neuropathic Pain,” “Phenytoin and Neuropathy,” and “Phenytoin and Neuropathic Pain.” With the results, the papers were reviewed using the PRISMA (Preferred Reporting in Systematic and Meta-Analyses) guideline.Results: A total of 58 randomized controlled trials were reviewed among 8 pharmacologic agents, which are organized by date and alphabetical order. Of the trials for ketamine, 15 showed some benefit for analgesia. Methadone had 3 positive trials, while amantadine and memantine each only had 2 trials showing NeuP analgesic properties. Dextromethorphan and valproic acid both had 4 randomized controlled trials that showed some NeuP treatment benefit while carbamazepine had over 8 trials showing efficacy. Finally, phenytoin only had 1 trial that showed clinical response in treatment.Conclusions: There are a variety of NMDAR antagonist agents that should be considered for treatment of NeuP. Nevertheless, continued and further investigation of the 8 pharmacologic agents is needed to continue to evaluate their efficacy for treatment of NeuP.

1 August 2018 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
PDF file
RARohit Aiyer
Rohit Aiyer
AGAmitabh Gulati
Amitabh Gulati
SGSemih Gungor
Semih Gungor
ABAnuj Bhatia
Anuj Bhatia
NMNeel Mehta
Neel Mehta
Clinical studies demonstrate that buprenorphine is a pharmacologic agent that can be used for the treatment of various types of painful conditions. This study investigated the efficacy of 5 different types of buprenorphine formulations in the chronic pain population. The literature was reviewed on PubMed/MEDLINE, EMBASE, Cochrane Database, clinicaltrials.gov, and PROSPERO that dated from inception until June 30, 2017. Using the population, intervention, comparator, and outcomes method, 25 randomized controlled trials were reviewed involving 5 buprenorphine formulations in patients with chronic pain: intravenous buprenorphine, sublingual buprenorphine, sublingual buprenorphine/naloxone, buccal buprenorphine, and transdermal buprenorphine, with comparators consisting of opioid analgesics or placebo. Of the 25 studies reviewed, a total of 14 studies demonstrated clinically significant benefit with buprenorphine in the management of chronic pain: 1 study out of 6 sublingual and intravenous buprenorphine, the only sublingual buprenorphine/naloxone study, 2 out of 3 studies of buccal buprenorphine, and 10 out of 15 studies for transdermal buprenorphine showed significant reduction in pain against a comparator. No serious adverse effects were reported in any of the studies. We conclude that a transdermal buprenorphine formulation is an effective analgesic in patients with chronic pain, while buccal buprenorphine is also a promising formulation based on the limited number of studies.

26 October 2016 in Pain Management
Verified
Journal Article
Closed access
RARohit Aiyer
Rohit Aiyer
RBRobert L Barkin
Robert L Barkin
ABAnurag Bhatia
Anurag Bhatia
SGSemih Gungor
Semih Gungor
Phantom limb pain (PLP) is a challenging chronic pain syndrome to treat with pharmacologic agents being first line of management. However, when these agents fail to provide pain relief, other interventions must be considered in a clinical setting. Spinal cord stimulation (SCS) has been shown to provide analgesia in PLP, and should be considered by clinicians. Methods: This PRISMA systematic review analyzes the efficacy of SCS for treatment of PLP. Results: After review of 12 studies, there are mixed results to base a conclusion on. Discussion: While there is some evidence of efficacy, due to the relatively small number of patients in each study, further research is needed to demonstrate the benefits of SCS for PLP.

1 July 2019 in Medicine
Verified
Journal Article
Open access
SGSemih Gungor
Semih Gungor
KFKara Fields
Kara Fields
RARohit Aiyer
Rohit Aiyer
AVAlejandro Gonzalez Della Valle
Alejandro Gonzalez Della Valle
ESEdwin P Su
Edwin P Su
Persistent postsurgical pain (PPP) is defined as the discomfort that lasts >3 months postoperatively. The primary aim of this retrospective study was to estimate the risk of developing moderate-to-severe PPP after primary total knee arthroplasty (TKA). The secondary goal was to explore potential predictors of this outcome. Data were collected via hospital arthroplasty registry and chart review. The risk of moderate-to-severe PPP, defined as ≥4 on the numerical rating scale (NRS) at minimum of 3 months post-surgery, was calculated. Multivariable logistic regression was used to estimate the association of patient demographics, diagnoses, length of hospital stay, and preoperative NRS with the odds of developing PPP. Exploratory, simple logistic regression was used to estimate the association of perioperative factors with the odds of developing PPP on a subset of patients (n = 72). The risk of PPP after TKA was 31.3% (95% confidence interval [CI]: 27.5–35.0) (n = 578). Every 2-point increase in baseline NRS was associated with 1.66 (95% CI: 1.37–2.03) times the odds of developing PPP (P < .001). African-Americans (vs whites) had 1.82 (95% CI: 1.03–3.22) times the odds of developing PPP (P = .040). Exploratory analysis suggested that the adductor canal saphenous nerve (vs femoral nerve) blocks were associated with 2.87 (95% CI: 1.00–8.26) times the odds of developing PPP (P = .049). This study estimated a high risk (31.3%) of moderate-to-severe PPP after primary TKA. This study suggested that higher preoperative pain scores might be associated with greater odds of developing PPP. Moreover, this study suggested the possibility that racial differences and types of peripheral nerve blocks might be associated with greater odds of developing moderate-to-severe PPP after TKA surgery. However, the evidence obtained from our exploratory analysis of limited data certainly requires further exploration in large-scale studies.

22 September 2017 in Pain Management
Verified
Journal Article
Closed access
SGSemih Gungor
Semih Gungor
RARohit Aiyer
Rohit Aiyer
Aim: To illustrate the anatomical and pathophysiological risks of epidural hematoma formation, other than direct needle trauma, after lumbar transforaminal epidural steroid injection in the setting of severe central canal stenosis. Case report: This case report presents the development of an epidural hematoma after lumbar transforaminal epidural steroid injection in a patient who has anatomical risk factor of severe lumbar spinal stenosis. The anatomic location of epidural hematoma was at the injected level, but on the contralateral side of the dura at a distance from the needle path. Epidural vascular anatomy and the potential mechanisms of bleeding in the epidural space in the absence of direct needle trauma, including the importance of injection pressures are discussed. Conclusion: This is the first reported case of an epidural hematoma on the contralateral side of the dura at a distance from the needle tip location, in the setting of severe central canal stenosis.

11 March 2020 in Neuromodulation: Technology at the Neural Interface
Verified
Journal Article
Closed access
PDF file
PGPriyanka Ghosh
Priyanka Ghosh
SGSemih Gungor
Semih Gungor